JD Schonhoft

Precision medicine

[Repare Therapeutics @RepareRx]

In the first, we present a novel and comprehensive dose-finding strategy from the Phase I/IIa TRESR trial with @SarahCannon_UK and @MSKCancerCenter.

[JD Schonhoft @JDSchonhoft]

Great meeting in Madrid at #islb23 and congrats to my colleague @iansilverman for being chosen to present our work incorporating liquid biopsy into drug development #liquidbiopsy #ddr

[Repare Therapeutics @RepareRx]

At the upcoming @AACR @theNCI @EORTC International Conference, Repare will present data from its ongoing Phase 1 MYTHIC clinical trial in a plenary session, in addition to multiple posters presentations. Learn more: https://t.co/2F5szRtcDL #Targets23

[Nature Medicine @NatureMedicine]

The oral #ATR kinase inhibitor #camonsertib is well tolerated in patients with DNA damage response-deficient #SolidTumors and displays encouraging anti-tumor activity, with the highest response rate in patients with #OvarianCancer.
https://t.co/KiePAdPz2l

[Repare Therapeutics @RepareRx]

We are pleased to present a new publication in @NatureMedicine with @MDAndersonNews and @MSKCancerCenter. This trial represents the most comprehensively analyzed and prospectively selected population of tumors treated with an ATR inhibitor. https://t.co/axm7Ql1XZd

[Repare Therapeutics @RepareRx]

Today at #AACR23 Clinical Trials Plenary Session, Repare disclosed initial data from our ongoing Phase 1/2 TRESR and ATTACC clinical trials evaluating camonsertib in combination with three PARP inhibitors in patients with #solidtumors. Full presentation: https://t.co/UxY5SZ7BR6

[Repare Therapeutics @RepareRx]

Today, Repare announced that data from the Phase I/II trials evaluating camonsertib in combination with three PARP inhibitors has been selected for a plenary oral presentation at #AACR23, in addition to two poster presentations for RP-6306. More details: https://t.co/4TN4WLzK9q

[Nasdaq Exchange @NasdaqExchange]

.@NasdaqExchange congratulates #NasdaqListed @RepareRx on its license and collaboration deal with @Roche. 🎉

The collaboration allows for the development of camonsertib (RP-3500) with potential to expand development into additional tumors and multiple combination studies.

[Clinical Cancer Research @CCR_AACR]

Serritella et al report on the results of first prospective trial of combining glucocorticoid receptor and androgen receptor antagonists in castration-resistant #ProstateCancer.
https://t.co/gB1Y4zVO8l
@aserritella1984 @jdschonhoft

[UroToday.com @urotoday]

Evaluating circulating tumor cells in patients on the #CARD trial. @EfstathiouEleni @MDAndersonNews joins @CaPsurvivorship @DanaFarber to highlight a preplanned biomarker analysis of patients on the CARD trial. #WatchNow on UroToday > https://t.co/q4GZmHzvcC @NEJM @sanofi

[Misha Beltran @mishabeltran]

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer. Nice collaboration with @EpicSciences Congrats @CinziaConted @DanaFarber @PCF_Science @Nature_NPJ
https://t.co/DaGRFVoL1h

[The PCCTC @ThePCCTC]

From the chair of our SOC, Dr. Howard I. Scher (@sloan_kettering) and colleagues, validation of the prognostic significance of pretreatment circulating tumor cells (CTC) in prostate cancer via Eur J Cancer: https://t.co/PInkV8ZeHO

[Andrew Armstrong @AarmstrongDuke]

Excited to share our latest CTC paper in metastatic CRPC on the importance of enumeration for prognosis! @EpicSciences @ThePCCTC @DukeGUCancer @PCF_Science https://t.co/otSx2NS70B

[Heather Chalfin @heather_chalfin]

Excited about the future of #CTCs in GU cancer - more work is needed! Thankful for the AUA Care Foundation Grant that got us started 5 years ago @apolo_andrea @EpicSciences @RareCyte @SUO_YUO @CarolynBestAUA @pienta_brady @michael_gorin @brady_urology @NCICCR_UroOnc

[Epic Sciences │ The Power of Clarity @EpicSciences]

#EpicSciences today announced it has entered into a global collaboration with Q² Solutions® to offer Illumina®’s TruSight Oncology 500 #liquidbiopsy ctDNA test to Epic’s global biopharmaceutical customers.
Press Release: https://t.co/82pdsM6a2z

[UroToday.com @urotoday]

@EpicSciences to present multiple abstracts at #ASCO20 highlighting the importance of CTCs in liquid biopsy data characterizes the role of CTCs in cancer prognosis and patient care. Details on UroToday > https://t.co/pIcxjN23bQ @ASCO

[Misha Beltran @mishabeltran]

SLFN11 expression in advanced prostate cancer and response to platinum. Congratulations @CinziaConted and team @ShengyuKu @loredana_puca @asbonerw @rdittamore @ElementoLab @DrScottTagawa @DanaFarber @WeillCornell @EpicSciences @PCF_Science
https://t.co/vl76igtk0y

[JD Schonhoft @JDSchonhoft]

@TonyDee07 @LisaMarieBoothe He said there is no evidence, not that the drug is good or bad, just that we don’t know yet.

[JD Schonhoft @JDSchonhoft]

@LisaMarieBoothe I think more an issue of spreading false hope for a completely unproven treatment

[The Onion @TheOnion]

New 23andMe Feature Connects Users To Others Who Share Genetic Tendency To Get Billed For $199 https://t.co/npvZBE9vfL